Earnings ·
Reports Q3 net loss of $95.7M and raises R&D expenses to $84.7M as cash runway extends into mid-2028
KLRAKailera Therapeutics, Inc.
Kailera Therapeutics reported a third-quarter 2026 net loss of $95.7 million, widening from $39.6 million in the prior-year period, driven by research and development expenses that surged to $84.7 million from $27.0 million. General and administrative costs also rose to $21.7 million from $13.1 million as the company expanded operations. Despite the increased burn rate, the firm reported cash, cash equivalents, and marketable securities of $1.04 billion at quarter-end, providing a funding runway into mid-2028. The company highlighted significant pipeline progress, including the completion of an End-of-Phase 2 meeting with the FDA for its oral ribupatide candidate, which is expected to enter global Phase 3 trials in the first half of 2027. Additionally, the injection form's Phase 2b data and safiglipron's Phase 2 results are anticipated mid-2027, while KAI-4729 is on track for Phase 1 initiation by year-end. Kailera Therapeutics operates as a clinical-stage biotechnology company focused on developing GLP-1-based therapeutic candidates for the treatment of obesity.